Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial

[1]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[2]  N. Habib,et al.  Identification of Adenovirus (Ad) Penton Base Neutralizing Epitopes by Use of Sera from Patients Who Had Received Conditionally Replicative Ad (Addl1520) for Treatment of Liver Tumors , 2003, Journal of Virology.

[3]  J. A. George,et al.  Gene therapy progress and prospects: adenoviral vectors , 2003, Gene Therapy.

[4]  J. Hsieh,et al.  Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy. , 2003, BioTechniques.

[5]  J. Nemunaitis,et al.  Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients , 2003, Cancer Gene Therapy.

[6]  C. Fuchs,et al.  Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Wadler,et al.  Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[9]  L. Wein,et al.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. , 2002, Cancer research.

[10]  M. Lusky,et al.  Transductional targeting with recombinant adenovirus vectors. , 2002, Current gene therapy.

[11]  B. Karlan,et al.  Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 , 2002, Cancer Gene Therapy.

[12]  R. Warren,et al.  Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. , 2002, Surgical oncology clinics of North America.

[13]  B. Karlan,et al.  A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer , 2002, Cancer Gene Therapy.

[14]  D. Sze,et al.  Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial , 2001, Gene Therapy.

[15]  H. Yeh,et al.  Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  D. Fraker,et al.  Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal carcinoma. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Kelly,et al.  E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. , 2001, Human gene therapy.

[19]  Suxing Liu,et al.  Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models , 2000, Cancer Gene Therapy.

[20]  L H Blumgart,et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.

[21]  L. Nielsen,et al.  The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies. , 1999, The American journal of pathology.

[22]  J. Roth,et al.  p53 tumor suppressor gene therapy for cancer. , 1999, Oncology.

[23]  L. Harris,et al.  Wild-type p53 induction mediated by replication-deficient adenoviral vectors. , 1999, Cancer research.

[24]  N. Lemoine,et al.  A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. , 1999, Human gene therapy.

[25]  R. Dummer,et al.  The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. , 1998, Human gene therapy.

[26]  B. Sugarman,et al.  Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. , 1998, Cytometry.

[27]  James M. Wilson,et al.  Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.

[28]  R. Herrmann,et al.  A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. , 1998, Human gene therapy.

[29]  H. Shepard,et al.  p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. , 1998, Clinical Cancer Research.

[30]  C. Henschke,et al.  Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. , 1997, Human gene therapy.

[31]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[32]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[33]  J. Wilson,et al.  Adenoviruses as gene-delivery vehicles. , 1996, The New England journal of medicine.

[34]  H. Shepard,et al.  Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. , 1996, Cancer gene therapy.

[35]  R. Bookstein,et al.  p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. , 1996, Seminars in oncology.

[36]  H. Shepard,et al.  Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.

[37]  S. Hirohashi,et al.  Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. , 1994, Cancer letters.

[38]  W. Shoemaker,et al.  Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury , 1994, Critical care medicine.

[39]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[40]  M. Schuler,et al.  Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.